Latest news and press releases about Nuvectis Pharma, Inc. (NVCT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases.
Price
| Price | $21.87 |
| Market Cap | $580M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 52.60 |
| EV / EBITDA | -19.35 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -169.47% |
| Return on Invested Capital | -317.86% |
| Return on Assets | -124.45% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARMP · CGEN · CRDF · CYBN · IPHA · MIST · MOLN
Explore sector: Healthcare · Biotechnology
More sections of NVCT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks